Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie is launching an ambitious late-stage eye study called NAAVIGATE, formall......

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CVS Health (CVS), BioMarin Pharmaceutical (BMRN) and......

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CVS Health (CVS), BioMarin Pharmaceutical (BMRN) and......

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie’s new early stage study, officially titled “A Phase 1b Study to Assess t......

Abbvie ($ABBV) announced an update on their ongoing clinical study. The study, officially titled “An Open-label Extension of Study M15-741 to Evalu......

An update from AbbVie ( ($ABBV) ) is now available. At AbbVie’s 2026 Annual Meeting of Stockholders held on May 8, 2026, shareholders elected four ......

In a report released on May 8, Luisa Hector from Berenberg Bank maintained a Buy rating on AbbVie, with a price target of $275.00. The company’s sh......

AbbVie ( ($ABBV) ) has been popular among investors this week. Here is a recap of the key news on this stock. AbbVie has completed a Phase 1a trial......

Vanguard S&P 500 ETF ($VOO) remains one of the most popular choices for investors seeking broad exposure to the U.S. stock market. However, as mark......

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) has completed a Phase 1a study titled “A Phase 1a Study to Evalua......